Press releases
- Press releases
- Browse
Press releases
Two papers on Embil's novel triple-active topical products (Neo-Penotran® Forte and Neo-Penotran® Forte-L) have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004 More
Protein drug development company Mycenax Biotech Inc. (GreTai, Taiwan: 4726) announced today that its rheumatoid arthritis and psoriasis drug TuNEX®, a biosimilar version of etanercept, has successfully completed a Phase I trial in South Korea and Phase I More
New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004. More
APR and the leading pharmaceutical company in Turkey Abdi Ibrahim have entered into an exclusive license agreement for the promotion, distribution and marketing of Ondansetron Rapidfilm® in Turkey; terms of the deal were not disclosed. More
Hamburg, December 10th, 2010
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.
Amarin h More
The International Contract Service Event (“ICSE”), taking place in Madrid from 9th until 11th October 2012, is co-located with the “CPhI Worldwide” – the biggest international fair for the pharmaceutical industry. More
APR, the drug developer and drug delivery technology provider headquartered in Balerna, Switzerland and its partner Labtec, the drug delivery technology developer headquartered in Langenfeld, Germany announce the submission of Zolmitriptan Oral Dispersibl More
APR Applied Pharma Research announces a 50mg diclofenac potassium sachet for drinkable solution, developed according to its new patented drug delivery technology useful to improve efficacy and safety of fast acting formulations containing diclofenac More
Two new Clinical Study reports of Neo-Penotran® Forte are to be presented at the 10'th International Congress on Infectious Diseases meeting to be held in Singapore between 11-14 March 2002. More
APR and Labtec announce the successful completion of the Pivotal Bioequivalence study for Ondansetron RapidFilm™ More
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2011 - 39 pages - $250
Sep 2010 - 37 pages - $250
Jan 2011 - 20 pages - $340
Jan 2011 - 54 pages - $340
Oct 2010 - 112 pages - $7,600
Sep 2011 - 40 pages - $250
Sep 2011 - 42 pages - $250
Sep 2010 - 38 pages - $250
Sep 2010 - 37 pages - $250
Sep 2011 - 43 pages - $250
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Year
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us